6-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

Form6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of August 2025

CommissionFile Number: 001-40678

EUDAHealth Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01

Eunos Techpark, Singapore 415979.

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110.

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

OtherEvents.

On August 28, 2025, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.

Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Exhibit99.1

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”).

EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition.

Chemokine is a Singapore based biotech company focused on molecular supplements and gene modulating formulations including, but not limited to, a next-generation immune health supplement it earlier granted EUDA exclusive worldwide distribution rights to, which EUDA and its subsidiaries will market under the brand name, Euda Helixé.

Chemokine was founded by its major shareholder, Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore’s national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.

WhatMakes Euda Helixé Different

Euda Helixé is designed to support energy, immune resilience, and cellular health using a formulation that goes beyond traditional supplements. It combines molecular deer placenta, marine collagen and bioactive antioxidants like astaxanthin, L-glutathione, grape seed oil, sea-buckthorn oil and refined avocado oil which it delivers through a capsule system that protects and delivers the ingredients for maximum absorption

Euda Helixé is built on a gene activation model designed to modulate gene expression by activating beneficial genes while silencing harmful ones.

AboutEUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

ForwardLooking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Chemokine, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Christensen Advisory

Linda Bergkamp

Phone: +1-480-614-3004

E-mail: linda.bergkamp@christensencomms.com